FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a KMT2A Translocation By Ogkologos - December 10, 2024 583 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AUGMENT-101 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR 2021 ASCO Annual Meeting Research Round Up: Advances in Genitourinary Cancers June 23, 2021 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 A winding journey into the world of children’s and young people’s... September 24, 2021 Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... November 13, 2020 Load more HOT NEWS Five Questions With…Fern, Christina, Mary, and Shelley. 9 Ways To Teach Kids To Be Confident (Without Teaching Them... Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence...
